Alys Pharmaceuticals is an R&D anchored immuno-dermatology focused company that aims to redefine the treatment landscape for dermatologic conditions with transformative solutions.

Alys Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Metric
Company Name	Alys Pharmaceuticals	Amylyx Pharmaceuticals, Inc.
Symbol		AMLX
MSH ID	COM:ALYSPHARMA	COM:AMYLYX
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Biotechnology
Country	US	US
Stage
Employee Count		384
Website	alyspharma.com	amylyx.com
LinkedIn		amylyx
Founders

Metric
Market Cap		140.77M
Enterprise Value
Monthly Web Traffic		9.71K
Web Traffic Growth		-0.23
Valuation
Raised Capital

Metric
Revenue		380.79M
Revenue (LTM)
Revenue (NTM)
Gross Profit		355.35M
EBITDA		39.89M
Operating Income		38.80M
Net Income		49.27M
EPS		0.73
Diluted EPS		0.70
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.93
Operating Profit Margin		0.10
EBITDA Margin		0.10
Net Profit Margin		0.13
Return on Equity		0.12
Return on Assets		0.10
Return on Capital Employed		0.09

COM:ALYSPHARMA

Alys Pharmaceuticals

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		566.01
P/B Ratio		2.48
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		1.09
EV Multiple		9.04

Metric
Days Sales Outstanding		36.41
Days Payables Outstanding		123.02
Days Inventory Outstanding		549.82
Operating Cycle		588.21
Cash Conversion Cycle		271.70
Asset Turnover		0.95

Metric
Operating Cash Flow		11.92M
Free Cash Flow		10.68M
Cash Flow to Debt		4.47
Operating Cash Flow/Sales		0.04
Free Cash Flow Yield		-0.05

Metric
Cash & Equivalents		170.20M
Accounts Receivable		-24.74M
Inventory		38.32M
Goodwill
Debt to Capitalization		0.01
Debt to Assets		0.01
Current Ratio		9.52
Quick Ratio		5.01

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.11
R&D to Revenue		0.36
SG&A to Revenue		0.34